This is the authors' abstract. We don't add key points for this paper.
Ribonuclease H1 (RNase H1) cleaves the RNA strand of DNA/RNA heteroduplexes and plays essential roles in R-loop resolution, mitochondrial DNA replication, and antisense oligonucleotide (ASO) activity. Because RNase H1 has also been implicated in ASO-induced cytotoxicity, considerable effort has been focused on minimizing its activation. Here we present a reverse strategy that harnesses RNase H1-mediated cytotoxicity for cancer therapy using an oncogenic microRNA (miR-21) as an intracellular trigger. A designed hairpin DNA/hairpin RNA pair undergoes a hybridization chain reaction to assemble long-nicked DNA/RNA heteroduplexes selectively in miR-21-overexpressing cells. The resulting heteroduplexes induce RNase H1-dependent cytotoxicity in cancer cells while exhibiting minimal effects on normal cells. Treatment also caused redistribution of the paraspeckle protein P54nrb from the nucleoplasm to the nucleoli, consistent with RNase-H1-associated nucleolar stress. Furthermore, lipid-nanoparticle-mediated delivery of the DNA/RNA heterohairpin pair significantly suppressed tumor growth in mice. These findings establish a therapeutic strategy that converts RNase H1, traditionally regarded as a source of oligonucleotide toxicity, into a mechanism for selective anticancer activity through the intracellular assembly of long DNA/RNA heteroduplexes.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Morihiro et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: